Life Sciences & Healthcare Innovation Hub

Our innovation hub for life sciences and healthcare is a demonstration of Cooley’s enduring commitment to the industry. It serves as a centralized point from which to access the insights and unparalleled experience of leading legal thinkers from across the firm and around the world.

Life Sciences Litigation: Biosimilars, 2024 Year in Review

Cooley lawyers recap the most important biosimilars cases, decisions, industry developments and government initiatives from 2024, as well as what to watch for in 2025.

January 23, 2025

ArsenalBio Closes Oversubscribed $325 Million Series C

A Cooley team advised Arsenal Biosciences, a clinical-stage programmable cell therapy company, on the close of its oversubscribed $325 million Series C financing round.

September 4, 2024

Tempus AI Announces $410.7 Million IPO

Cooley advised Tempus AI, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, on its $410.7 million initial public offering.

June 13, 2024

Cooley Defeats Preliminary Injunction for Liquidia in Litigation With United Therapeutics

A Cooley team successfully defeated a preliminary injunction filed by United Therapeutics that sought to block the launch of client Liquidia’s Yutrepia (treprostinil) inhalation powder for the treatment of pulmonary hypertension associated with interstitial lung disease.

June 3, 2024

RayzeBio Signs Approximately $4.1 Billion Acquisition Agreement With Bristol Myers Squibb

Cooley advised RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company with an innovation-leading position in actinium-based RPTs and a pipeline of potentially first-in-class and best-in-class drug development programs, on its definitive agreement to be acquired by Bristol Myers Squibb.

December 26, 2023

SystImmune Announces Global Strategic Collaboration With Bristol Myers Squibb

A Cooley team advised SystImmune, a clinical-stage biopharmaceutical company, on its exclusive license and collaboration agreement with Bristol Myers Squibb for SystImmune’s BL-B01D1.

December 11, 2023